KFBIO Cytology AI KF-AI-LBC: Advancing Cervical Cancer Screening with Precision and Efficiency

AI Is Transforming Digital Cytology

Artificial intelligence (AI) is rapidly changing digital pathology. Today, more cytology laboratories are using AI to improve cervical cancer screening.

Recently, the American Society of Cytopathology (ASC) Digital Cytology Task Force highlighted AI’s growing role in cytology. According to the Task Force, AI can improve diagnostic accuracy, streamline laboratory workflows and support both gynecological (GYN) and non-GYN cytology.

Among the commercial platforms discussed in its review, KFBIO’s AI-assisted cytology system was recognized as a fully integrated digital pathology solution.

The platform combines:

• Whole slide imaging (WSI)
• Deep learning algorithms
• Digital pathology workflow
• AI-assisted cervical cancer screening

Together, these technologies help laboratories improve efficiency while maintaining diagnostic quality.

The Shift Toward AI in Cytology

Traditional Pap smear screening depends heavily on manual microscopy.

However, manual screening is time-consuming and can produce different results between observers.

Fortunately, liquid-based cytology (LBC) and whole slide imaging are changing this workflow.

As more laboratories adopt digital pathology, AI is becoming an important clinical tool rather than a future concept.

According to the ASC Digital Cytology Task Force, AI can support:

• Primary screening
• Case classification
• Quality assurance

These advantages are especially valuable in high-volume cervical cancer screening programs.

Why KFBIO Stands Out

In its 2023 white paper, the ASC Task Force evaluated several commercial AI platforms for Pap test screening.

Among them, KFBIO was recognized for providing a complete digital cytology ecosystem.

Rather than offering only an AI algorithm, KFBIO integrates the entire workflow, including:

• Slide preparation
• Whole slide scanning
• Laboratory Information System (LIS) integration
• AI analysis
• Digital diagnostic viewer

As a result, laboratories can manage the entire cervical cancer screening process on one platform.

This integrated approach also helps simplify workflow management and supports laboratories that are adopting AI-enhanced screening.

Consequently, KFBIO has become an important provider of digital cytology solutions in markets moving toward intelligent pathology.

How KFBIO Cervical Cancer AI Works

The KFBIO Cytology AI platform uses a deep learning algorithm trained with more than 43,000 annotated liquid-based cytology (LBC) Pap test samples.

First, laboratory staff prepare slides using standard liquid-based cytology methods.

Next, KFBIO high-resolution whole slide scanners digitize the slides.

The scanners support z-stacking, which keeps different focal planes in clear focus.

This capability is especially important for cytology specimens because cells are distributed across different depths.

After digitization, the AI analyzes the entire whole slide image.

It automatically identifies and highlights regions that may require closer review, including:

• Squamous abnormalities
• Glandular abnormalities
• Potential infectious organisms such as Candida and Trichomonas
• Other cytomorphological features associated with dysplasia or malignancy

Instead of manually reviewing thousands of cells, cytotechnologists and pathologists receive an intuitive gallery view of AI-selected regions.

As a result, they can focus on clinically significant findings more efficiently while reducing repetitive screening work.

Reported Performance and Clinical Benefits

In cervical cancer screening, high sensitivity is essential for detecting abnormal cells as early as possible.

According to KFBIO’s validation data, the Cytology AI platform delivers strong screening performance.

Reported results include:

• Sensitivity ≥98.2% for detecting cervical lesions
• Specificity ≥63.5%
• Higher screening throughput
• Fewer slides requiring full manual review

These results show that the platform is well suited for high-volume laboratories.

More importantly, laboratories can improve efficiency without reducing diagnostic confidence.

By allowing AI to handle repetitive screening tasks, cytotechnologists and pathologists can spend more time reviewing complex or suspicious cases.

As a result, laboratories can optimize their workflow while maintaining high screening quality.

Seamless Integration into Existing Laboratory Workflows

Introducing AI should not disrupt routine laboratory operations.

Therefore, KFBIO designed its Cytology AI platform to integrate smoothly with existing workflows.

The platform supports:

• Laboratory Information System (LIS) connectivity
• Hospital Information System (HIS) integration
• Cloud-based image management
• On-premises image management
• Quality control
• Complete audit trails

Because the platform works with existing laboratory systems, laboratories can adopt AI more efficiently and reduce implementation challenges.

This flexible deployment model also allows laboratories to choose the solution that best matches their IT infrastructure and data management requirements.

Built for Clinical Compliance

Clinical AI solutions must meet strict regulatory requirements.

KFBIO’s Cytology AI platform has received both CE marking and China NMPA certification for cervical cancer screening.

These certifications demonstrate the platform’s compliance with recognized clinical and regulatory standards.

As a result, laboratories can implement the solution with greater confidence in regulated healthcare environments.

The Future of AI in Cytology

AI is rapidly expanding beyond cervical cancer screening.

According to the ASC Digital Cytology Task Force, future AI applications may include:

• Non-GYN cytology, such as urine, body fluids and fine-needle aspiration (FNA)
• Rapid On-Site Evaluation (ROSE)
• Biomarker quantification
• Prognostic scoring

As digital pathology continues to evolve, laboratories will rely on AI across more clinical applications.

KFBIO has designed its platform to grow with these changing needs.

Its scalable architecture supports future AI development while helping laboratories transition toward fully digital cytology services.

Why Choose KFBIO Cytology AI?

Modern laboratories need more than an AI algorithm.

They need a complete solution that supports every stage of the digital cytology workflow.

KFBIO provides an integrated platform that combines advanced imaging, intelligent analysis and workflow management.

Key advantages include:

Complete Digital Pathology Ecosystem

KFBIO connects slide preparation, whole slide imaging, AI-assisted review and digital diagnosis in one workflow.

This integrated approach simplifies laboratory operations and improves efficiency.

High Screening Accuracy and Efficiency

The platform combines high sensitivity with AI-assisted screening.

As a result, laboratories can reduce repetitive manual work while maintaining diagnostic quality.

Clinical-Ready Regulatory Compliance

CE marking and NMPA certification support clinical implementation in multiple healthcare markets.

Scalable AI Platform

The platform can support additional cytology applications as AI technology continues to evolve.

This flexibility helps laboratories protect their long-term investment in digital pathology.

Conclusion

Digital cytology is entering a new era.

AI is helping laboratories improve efficiency, standardize workflows and support more consistent screening.

KFBIO’s KF-AI-LBC Cytology AI platform combines whole slide imaging, deep learning and digital pathology workflow management into one integrated solution.

Instead of replacing cytotechnologists and pathologists, AI supports them by reducing repetitive work and highlighting clinically important findings.

As digital pathology adoption continues to grow, KFBIO remains committed to helping laboratories build smarter, more efficient and more accurate cervical cancer screening workflows.

---

References & Learn More:

• • American Society of Cytopathology Task Force White Paper: Read the Full Article

  • KFBIO Digital Cytology Platform: Visit KFBIO Pathology AI

  • KFBIO Cervical Cancer AI Overview: Cervical Cancer Diagnosis with AI

---

“KFBIO provides an integrated AI-assisted digital cytology platform for cervical cancer screening, demonstrating high sensitivity (≥98.2%) and specificity (≥63.5%) in detecting squamous and glandular lesions.”